Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Applied Digital Corporation (APLD) vs Eli Lilly And Co (LLY) Price & Performance

Applied Digital CorporationTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Applied Digital Corporation vs Eli Lilly And Co — how do they compare? Applied Digital Corporation trades at $31.45 (market cap $8.37B), while Eli Lilly And Co trades at $1,215.6 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 131.4× Applied Digital Corporation's market cap, and Eli Lilly And Co pays a 0.56% dividend while Applied Digital Corporation pays none. Which is the better fit depends on your goals.

APLDLLY
Market Cap
$8.37B$1.10T
Sector
TechnologyHealth
52-Week High
$49.65$1.24K
52-Week Low
$13.89$639.43
Enterprise Value
$11.87B$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Applied Digital Corporation

Applied Digital (APLD) trades at $29.22, up 1.25% with bearish technical signals despite unanimous analyst buy ratings. The company shows explosive revenue growth with Q4 2026 revenue surging 407% to $258.7M but continues posting significant losses with negative profit margins. Recent news highlights $36 billion in contracted AI infrastructure revenue and insider selling activity.

While analyst consensus targets $72.36 (147% upside), the stock faces execution risks from massive capital expenditures, negative cash flow, and challenging profitability metrics. The AI infrastructure build-out offers substantial growth potential but requires careful monitoring of financing needs and construction timelines.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Applied Digital Corporation

Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.

Read more on APLD

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY